Olimab 60mg Injection

Denosumab is a monoclonal antibody that works by targeting and blocking a protein called RANKL, which plays a key role in the formation and activity of cells that break down bone tissue. By inhibiting this protein, Denosumab helps slow bone loss and allows bone density to gradually improve, supporting stronger, healthier bones over time. It is commonly used to treat osteoporosis in postmenopausal women and in men at increased risk of fractures, helping to reduce the risk of spine, hip, and other bone fractures. Denosumab is also used to help prevent bone-related complications, such as fractures, in patients with certain cancers that have spread to the bone, as well as to treat bone loss related to certain cancer treatments. Additionally, it is used to manage giant cell tumor of bone, a rare but locally aggressive bone tumor. The medication is administered by injection, typically given every six months for osteoporosis treatment or on a more frequent schedule for certain cancer-related bone conditions, as directed by a healthcare provider. Regular monitoring, including calcium levels and periodic bone density scans, is an important part of treatment to help track progress and ensure safety. Many patients experience meaningful improvement in bone density and reduced fracture risk with consistent use of Denosumab. As with all specialized bone health therapies, Denosumab injection should be administered under the guidance of a healthcare provider experienced in treating the specific condition.